

APR-24-2006 MON 10:08 AM astra zeneca r&d boston

FAX NO. 17818394121

P. 01/02

RECEIVED
CENTRAL FAX CENTER

APR 24 2006

PTO/SB/82 (03-04)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Approved for use through 11/30/2005. OMB 0651-0035

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Application Number	10/555,586
	Filing Date	November 4, 2005
	First Named Inventor	Li-Ming Gan
	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	100816-1P US

I hereby revoke all previous powers of attorney given in the above-identified application.

 A Power of Attorney is submitted herewith.

OR

 I hereby appoint the practitioners associated with the Customer Number: 44992 Please change the correspondence address for the above-identified application to: The address associated with Customer Number: 44992

OR

<input type="checkbox"/> Firm or Individual Name	AstraZeneca Pharmaceuticals LP	
--	--------------------------------	--

Address	Global Intellectual Property 35 Gatehouse Drive	
---------	--	--

City	Waltham	
------	---------	--


Country	USA	State	MA	Zip	02451
---------	-----	-------	----	-----	-------

Telephone	(781) 839-4000	Fax	(781) 839-4121
-----------	----------------	-----	----------------

I am the:

 Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature			
Name	Tracey Bryant		
Date	13 JANUARY 2006	Telephone	+44 (0) 1625 513228
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.			
<input checked="" type="checkbox"/>	Total of <u>1</u> forms are submitted.		

RECEIVED
CENTRAL FAX CENTER

A/R 24 2006

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Li-Ming Gan and Lars-Eric Marberg
 Application No.: 10/555,586 Filed: November 4, 2005
 Entitled: ASSAY

(Name of Assignee) AstraZeneca AB, a Corporation
 (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest; or
 2. an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is %
 in the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: To:
 The document was recorded in the United States Patent and Trademark Office at
 Reel , Frame , or for which a copy thereof is attached.

2. From: To:
 The document was recorded in the United States Patent and Trademark Office at
 Reel , Frame , or for which a copy thereof is attached.

3. From: To:
 The document was recorded in the United States Patent and Trademark Office at
 Reel , Frame , or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.
 [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Tracey Bryant
 Signature

13 JANUARY 2006
 Date

Tracey Bryant
 Printed or Typed Name
 Authorized Signer for Assignee
 Title: Patent Director, Oncology & Infection

Telephone Number
 +44 (0) 1625 513228